Recap: Danaher Q4 Earnings

 

Shares of Danaher DHR rose 0.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 62.50% year over year to $2.08, which beat the estimate of $1.87.

Revenue of $6,760,000,000 rose by 38.87% year over year, which beat the estimate of $6,530,000,000.

Looking Ahead

Danaher hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Jan 28, 2021

Time: 08:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/758/39359

Price Action

52-week high: $248.32

Company's 52-week low was at $119.60

Price action over last quarter: down 4.50%

Company Profile

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which adds to its life sciences segment.

Posted In: BZI-RecapsEarningsNews